Relation combines artificial intelligence with experimental biology to discover and develop therapeutics across immunology, metabolic and bone disease indications. Led by CEO David Roblin, the company builds integrated AI and laboratory platforms that span the entire drug-development cycle, from target identification to clinical candidate optimization. Its current portfolio includes multiple programs in each of its three focus disease areas. The firm positions itself as a full-stack drug developer rather than a tool provider, aiming to bring proprietary medicines to market. Proceeds from its latest financing will be used to broaden operations and intensify R&D. No revenue, user, or clinical milestone metrics were disclosed in the article.

Total raised

$61M

Funding rounds

2

Latest round

Equity

Latest activity

Dec 2025